Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of ACE-031 and Follistatin 344 — mechanism, side effects, legal status, and pricing.
ACE-031 (ramatercept) is a soluble fusion protein of the activin receptor IIB (ActRIIB) extracellular domain and human IgG1 Fc, developed by Acceleron Pharma as a myostatin/activin ligand trap for muscle-wasting disorders. Clinical development was HALTED in 2011 after unexpected vascular adverse events (epistaxis, telangiectasia) attributed to off-target BMP-9/10 inhibition. NOT FDA-approved; all further development was terminated. Now sold only as a grey-market research chemical. WADA-prohibited (myostatin inhibitor).
Follistatin 344 is a recombinant form of the naturally-occurring glycoprotein (344-residue splice variant) that inhibits activin and myostatin signaling. Clinical validation exists ONLY through small AAV gene-therapy phase 1/2 trials in Becker muscular dystrophy; recombinant injectable protein sold on the grey market has no clinical evidence. NOT FDA-approved. WADA-prohibited (myostatin inhibitor) and banned in competitive sport.
ACE-031
Follistatin 344
Category
Legal Status
Mechanism
Side Effects
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
ACE-031
1 vendor lists this, but none clear the trust bar (score ≥70) yet.
Check ACE-031 prices →Follistatin 344
COA corpus from Disclosed Labs — independently tested batches only.
ACE-031
1
COAs
99.8%
Avg purity
1
Labs
Follistatin 344
2
COAs
99.5%
Avg purity
2
Labs
Phase 2 in ambulatory boys with Duchenne muscular dystrophy was terminated early in 2011 after unexpected nose-bleeds and telangiectasia were observed (attributed to off-target BMP-9/10 neutralization); published results later showed no significant 6MWT benefit vs. placebo in the truncated trial (Campbell et al., Muscle & Nerve, 2017; PMID 27462804). A single-ascending-dose Phase 1 study in healthy postmenopausal women (Attie et al., Muscle & Nerve, 2013; PMID 23169607) showed dose-dependent modest lean-mass increase but also the same vascular signal. Acceleron formally discontinued ACE-031 in 2013 and pivoted to other ActRII programs. No FDA approval; development TERMINATED for vascular safety. WADA-prohibited.
AAV1-FS344 intramuscular gene therapy Phase 1/2a in Becker muscular dystrophy (n=6) reported improved 6-minute walk test and quadriceps volume changes (Mendell et al., Molecular Therapy, 2015). Preclinical mdx mouse and cynomolgus primate studies showed durable muscle mass and strength increases (Kota et al., Science Translational Medicine, 2009). Recombinant Follistatin-344 protein sold as an injectable research chemical has NO validated human clinical data — all positive human evidence is from AAV gene therapy, not peripheral protein injection. Not FDA-approved. WADA-prohibited at all times.
ACE-031 and Follistatin 344 are both in the Performance category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Contraindications
Lab Testing
Disclosed Labs